| Eli Lilly (Suisse) SA - Mounjaro 5 mg, solution for injection in vial |
| 69415 | | 02 | | Mounjaro 5 mg | | solution for injection in vial | | A10BX | | Andere orale Antidiabetika | | 09.07.2024 | | |
|
| Composition |
| tirzepatidum 5 mg, dinatrii phosphas heptahydricus, natrii chloridum, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile, ad solutionem pro 0.5 ml corresp. natrium 1.8 - 1.9 mg. |
| Packungsbestandteile |
| solution for injection in vial | | | | | | Principe actif | Concentr. |
|---|
| Tirzepatidum | 5mg / 0.5ml |
| | | | Agents auxilliaires |
|---|
| Acidum Hydrochloridum | | Disodium Phosphate Heptahydrate | | Sodium Chlorure | | Sodium Hydroxide |
|
|
| numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 002 | | DDP | DDP | B | | Non | | 008 | 4 | DDP | DDP | B | | Non |
|
